Page last updated: 2024-12-06

ethafluralin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID41381
CHEMBL ID1256703
CHEBI ID81988
SCHEMBL ID55014
MeSH IDM0089083

Synonyms (55)

Synonym
el161
sonalan
ethalfluralin
(2,6-dinitro-4-(trifluoromethyl)phenyl)ethyl(2-methylprop-2-enyl)amine
55283-68-6
n-ethyl-n-(2-methylallyl)-2,6-dinitro-4-(trifluoromethyl)aniline
NCGC00163893-01
caswell no. 453b
ethafluralin
p-toluidine, 2,6-dinitro-n-ethyl-n-(2-methyl-2-propenyl)-alpha,alpha,alpha-trifluoro-
ethalfluraline [iso-french]
einecs 259-564-3
epa pesticide chemical code 113101
n-ethyl-n-(2-methylallyl)-2,6-dinitro-4-trifluoromethylaniline
ethalfluralin [ansi:bsi:iso]
el 161
n-ethyl-n-(2-methyl-2-propenyl)-2,6-dinitro-4-(trifluoromethyl)benzenamine
compound 94961
benzenamine, n-ethyl-n-(2-methyl-2-propenyl)-2,6-dinitro-4-(trifluoromethyl)-
n-ethyl-alpha,alpha,alpha-trifluoro-n-(2-methylallyl)-2,6-dinitro-p-toluidine
buvilan
brn 2907084
el-161
n-ethyl-n-(2-methylprop-2-en-1-yl)-2,6-dinitro-4-(trifluoromethyl)aniline
NCGC00163893-02
n-ethyl-n-(2-methylprop-2-enyl)-2,6-dinitro-4-(trifluoromethyl)aniline
NCGC00163893-03
C18827
cas-55283-68-6
tox21_301082
dtxcid6012386
NCGC00254983-01
dtxsid8032386 ,
CHEMBL1256703
chebi:81988 ,
hsdb 7545
benzenamine, n-ethyl-n-(2-methyl-2-propen-1-yl)-2,6-dinitro-4-(trifluoromethyl)-
51dka727xq ,
unii-51dka727xq
ethalfluraline
AKOS015888387
ethalfluralin [hsdb]
n-ethyl-n-methallyl-4-trifluoromethyl-2,6-dinitroaniline
ethalfluralin [mi]
n-ethyl-.alpha.,.alpha.,.alpha.-trifluoro-n-(2-methylallyl)-2,6-dinitro-p-toluidine
ethalfluralin [iso]
SCHEMBL55014
n-ethyl-n-(2-methyl-2-propenyl)-2,6-dinitro-4-(trifluoromethyl)aniline #
p-toluidine, 2,6-dinitro-n-ethyl-n-(2-methyl-2-propenyl)-.alpha.,.alpha.,.alpha.-trifluoro-
sonalen (salt/mix)
ethalfluralin, pestanal(r), analytical standard
ethalfluralin 10 microg/ml in cyclohexane
FT-0728331
Q22807464
benzenamine,n-ethyl-n-(2-methyl-2-propenyl)-2,6-dinitro-4-(trifluoromethyl)-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
pregnane X receptorRattus norvegicus (Norway rat)Potency56.23410.025127.9203501.1870AID651751
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency0.19493.189029.884159.4836AID1224846
AR proteinHomo sapiens (human)Potency29.35640.000221.22318,912.5098AID1259243; AID1259247
retinoid X nuclear receptor alphaHomo sapiens (human)Potency58.19650.000817.505159.3239AID1159531
pregnane X nuclear receptorHomo sapiens (human)Potency19.26310.005428.02631,258.9301AID1346982; AID720659
thyroid stimulating hormone receptorHomo sapiens (human)Potency14.95160.001628.015177.1139AID1224843; AID1224895
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.17780.010039.53711,122.0200AID588547
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency68.58960.000323.4451159.6830AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.58960.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID522807Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin S6I mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522813Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235V mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522805Antimicrobial activity against Toxoplasma gondii RH infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522808Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin F24H mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522815Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243C mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522811Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235L mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522810Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin L136F mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522816Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243S mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522809Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin H28Q mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522812Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235T mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522814Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin T239I mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522806Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin V4L mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.69)18.7374
1990's1 (7.69)18.2507
2000's4 (30.77)29.6817
2010's5 (38.46)24.3611
2020's2 (15.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]